<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpan...

<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">NEW YORK</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">Aug. 17, 2026</span> /PRNewswire/ --</p>
    <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
                <p xmlns="http://www.w3.org/1999/xhtml">
                    <img xmlns="http://www.w3.org/1999/xhtml" src="https://mmx.prnewswire.com/media/MS1118010/Rosen-Law-Firm-Logo.jpg?id=OA2890323" title="Rosen Law Firm Logo" alt="Rosen Law Firm Logo"></img>
                </p>
    </div>
<p xmlns="http://www.w3.org/1999/xhtml">Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/AARD">AARD</a>): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the &#34;Registration Statement&#34;) issued in connection with Aardvark&#39;s February 13, 2025 initial public offering (&#34;IPO&#34;); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the &#34;Class Period&#34;). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 13, 2026.</p><p xmlns="http://www.w3.org/1999/xhtml">So what: If you purchased Aardvark securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.</p><p xmlns="http://www.w3.org/1999/xhtml">What to do next: To join the Aardvark class action, go to <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4753768-1&amp;h=2419546382&amp;u=https%3A%2F%2Frosenlegal.com%2Fcases%2Faardvark-therapeutics-inc%2Fjoin&amp;a=https%3A%2F%2Frosenlegal.com%2Fcases%2Faardvark-therapeutics-inc%2Fjoin" target="_blank" rel="nofollow">https://rosenlegal.com/cases/aardvark-therapeutics-inc/join</a> or call Phillip Kim, Esq. toll-free at 866-767-3653 or email <a xmlns="http://www.w3.org/1999/xhtml" href="mailto:case@rosenlegal.com" target="_blank" rel="nofollow">case@rosenlegal.com</a> for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.</p><p xmlns="http://www.w3.org/1999/xhtml">Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs&#39; Bar. Many of the firm&#39;s attorneys have been recognized by Lawdragon and Super Lawyers.</p><p xmlns="http://www.w3.org/1999/xhtml">Details of the case: According to the lawsuit, in the Registration Statement and throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Aardvark&#39;s business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) ARD-101 was less safe than defendants had led investors to believe; (2) accordingly, ARD-101&#39;s clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants&#39; public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.</p><p xmlns="http://www.w3.org/1999/xhtml">To join the Aardvark class action, go to <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4753768-1&amp;h=2419546382&amp;u=https%3A%2F%2Frosenlegal.com%2Fcases%2Faardvark-therapeutics-inc%2Fjoin&amp;a=https%3A%2F%2Frosenlegal.com%2Fcases%2Faardvark-therapeutics-inc%2Fjoin" target="_blank" rel="nofollow">https://rosenlegal.com/cases/aardvark-therapeutics-inc/join</a> or call Phillip Kim, Esq. toll-free at 866-767-3653 or email <a xmlns="http://www.w3.org/1999/xhtml" href="mailto:case@rosenlegal.com" target="_blank" rel="nofollow">case@rosenlegal.com</a> for information on the class action.</p><p xmlns="http://www.w3.org/1999/xhtml">No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor&#39;s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.</p><p xmlns="http://www.w3.org/1999/xhtml">Follow us for updates on LinkedIn: <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4753768-1&amp;h=3975556643&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm&amp;a=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm" target="_blank" rel="nofollow">https://www.linkedin.com/company/the-rosen-law-firm</a>, on Twitter: <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4753768-1&amp;h=3599918199&amp;u=https%3A%2F%2Ftwitter.com%2Frosen_firm&amp;a=https%3A%2F%2Ftwitter.com%2Frosen_firm" target="_blank" rel="nofollow">https://twitter.com/rosen_firm</a> or on Facebook: <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4753768-1&amp;h=649031002&amp;u=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F&amp;a=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F" target="_blank" rel="nofollow">https://www.facebook.com/rosenlawfirm/</a>.</p><p xmlns="http://www.w3.org/1999/xhtml">Attorney Advertising. Prior results do not guarantee a similar outcome.</p><p xmlns="http://www.w3.org/1999/xhtml">Contact Information:</p><p xmlns="http://www.w3.org/1999/xhtml">     Laurence Rosen, Esq.<br xmlns="http://www.w3.org/1999/xhtml"></br>     Phillip Kim, Esq.<br xmlns="http://www.w3.org/1999/xhtml"></br>     The Rosen Law Firm, P.A.<br xmlns="http://www.w3.org/1999/xhtml"></br>     275 Madison Avenue, 40th Floor<br xmlns="http://www.w3.org/1999/xhtml"></br>     New York, NY 10016<br xmlns="http://www.w3.org/1999/xhtml"></br>     Tel: (212) 686-1060<br xmlns="http://www.w3.org/1999/xhtml"></br>     Toll Free: (866) 767-3653<br xmlns="http://www.w3.org/1999/xhtml"></br>     Fax: (212) 202-3827<br xmlns="http://www.w3.org/1999/xhtml"></br>     <a xmlns="http://www.w3.org/1999/xhtml" href="mailto:case@rosenlegal.com" target="_blank" rel="nofollow">case@rosenlegal.com</a><br xmlns="http://www.w3.org/1999/xhtml"></br>     <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4753768-1&amp;h=3145073595&amp;u=http%3A%2F%2Fwww.rosenlegal.com%2F&amp;a=www.rosenlegal.com" target="_blank" rel="nofollow">www.rosenlegal.com</a></p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=DC27668&amp;sd=2026-08-17"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/aard-investors-have-opportunity-to-lead-aardvark-therapeutics-inc-securities-fraud-lawsuit-302853055.html" target="_blank">https://www.prnewswire.com/news-releases/aard-investors-have-opportunity-to-lead-aardvark-therapeutics-inc-securities-fraud-lawsuit-302853055.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE THE ROSEN LAW FIRM, P. A.</p>

AARD

AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit

Rosen Law Firm files AARD securities class action over IPO disclosures

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;p xmlns=&quot;http://www.w3.org/1999/xhtml&quot;&gt;&lt;span xmlns=&quot;http://www.w3.org/1999/xhtml&quot; class=&quot;legendSpan...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Rosen Law Firm alleges Aardvark misled investors about ARD-101 safety and program prospects, triggering potential damages. The action targets securities tied to AARD&#039;s Feb. 13, 2025 IPO and class-period filings through May 14, 2026, with a lead plaintiff deadline of Oct. 13, 2026. No class has been certified yet; recoveries would be contingency-based.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Rosen Law Firm files securities class action against AARD.</li><li>Lawsuit alleges misstatements in AARD&#039;s IPO disclosures and Class Period.</li><li>Class Period spans Feb 13, 2025 IPO to May 14, 2026.</li><li>Lead plaintiff deadline is Oct 13, 2026.</li><li>No certification yet; potential recovery possible under contingency.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Aardvark Therapeutics, Inc. (AARD)</strong>: Subject of securities-fraud lawsuit; potential sentiment risk.</li><li><strong>Rosen Law Firm (N/A)</strong>: Plaintiff-law firm issuing announcement; no direct market impact.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. Fits due to securities class-action filing; could affect perception and volatility, but not yet proven to affect fundamentals.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Legal developments and potential settlements could drive volatility in AARD.</li><li>Lead plaintiff deadline Oct 13, 2026 adds event risk into Q4 2026.</li><li>No class certification yet; material impact remains uncertain.</li><li>Market reaction may be muted absent new material facts.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Filed by Rosen Law Firm on behalf of AARD investors.</li><li>IPO date: February 13, 2025.</li><li>Class Period: February 13, 2025 – May 14, 2026.</li><li>Lead plaintiff deadline: October 13, 2026.</li><li>No class certified yet.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term risk modestly negative; longer-term impact hinges on lawsuits and class certification.</p>
  </section>
</section>


<article>
  <header>
    <h1>AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit</h1>
  </header>

  <section>
    <p>NEW YORK, Aug. 17, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/AARD">AARD</a>): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than <strong>October 13, 2026</strong>.</p>
    <p>Investors who purchased Aardvark securities may be entitled to compensation without out-of-pocket fees or costs through a contingency fee arrangement, under the terms of the proposed class action.</p>
  </section>

  <section>
    <h2>Class Action Details and How to Participate</h2>
    <p>What to do next: To join the Aardvark class action, go to <a href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4753768-1&amp;h=2419546382&amp;u=https%3A%2F%2Frosenlegal.com%2Fcases%2Faardvark-therapeutics-inc%2Fjoin&amp;a=https%3A%2F%2Frosenlegal.com%2Fcases%2Faardvark-therapeutics-inc%2Fjoin" target="_blank" rel="nofollow">https://rosenlegal.com/cases/aardvark-therapeutics-inc/join</a> or call Phillip Kim, Esq. toll-free at <strong>866-767-3653</strong> or email <a href="mailto:case@rosenlegal.com" target="_blank" rel="nofollow">case@rosenlegal.com</a> for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than <strong>October 13, 2026</strong>. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.</p>
    <p>Why Rosen Law: We encourage

Rosen Law Firm alleges Aardvark misled investors about ARD-101 safety and program prospects, triggering potential damages. The action targets securities tied to AARD's Feb. 13, 2025 IPO and class-period filings through May 14, 2026, with a lead plaintiff deadline of Oct. 13, 2026. No class has been certified yet; recoveries would be contingency-based.

News insight

AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit

AI summary

Sentiment rationale

Key facts

Legal